Lumos Pharma to Report Second Quarter 2023 Financial Results and Host Conference Call on August 9, 2023
26 Julio 2023 - 8:00AM
Lumos Pharma, Inc. (NASDAQ:LUMO), a biopharmaceutical company
advancing an oral therapeutic candidate for Pediatric Growth
Hormone Deficiency (PGHD) through Phase 2 clinical trials,
announced it will report its second quarter 2023 financial results
after market close on Wednesday, August 9, 2023. The company will
host a conference call and webcast at 4:30 PM ET that day to
discuss these financial results and provide an update on clinical
and corporate activities. A question-and-answer session will follow
the prepared remarks.
Investors and the general public are invited to
listen to the conference call. To access the call by phone, please
click on this Registration Link, complete the form and you will be
provided with dial in details and a PIN. To avoid delays, we
encourage participants to dial into the conference call ten minutes
ahead of the scheduled start time. The webcast may be accessed
through this Webcast Link and may also be found in the
“Investors & Media” section of the Lumos Pharma website, under
“Events & Presentations.” A replay of the call will be
available after the date of the call and may be accessed through
the same link above or found on our website.
About Lumos Pharma
Lumos Pharma, Inc. is a clinical stage
biopharmaceutical company focused on the development and
commercialization of therapeutics for rare diseases. Lumos
Pharma was founded and is led by a management team with
longstanding experience in rare disease drug development. Lumos
Pharma’s lead therapeutic candidate is LUM-201, an oral growth
hormone stimulating small molecule, currently being evaluated in a
Phase 2 clinical trial, the OraGrowtH210 Trial, a PK/PD trial, the
OraGrowtH212 Trial, and a switch trial, the OraGrowtH213 Trial for
the treatment of Pediatric Growth Hormone Deficiency (PGHD). If
approved by the FDA, LUM-201 would provide an orally administered
alternative to recombinant growth hormone injections that PGHD
subjects otherwise endure for many years of treatment. LUM-201 has
received Orphan Drug Designation in both the US and EU. For more
information, please visit https://lumos-pharma.com/.
Investor & Media Contact:
Lisa MillerLumos Pharma Investor
Relations512-792-5454ir@lumos-pharma.com
Source: Lumos Pharma, Inc.
Lumos Pharma (NASDAQ:LUMO)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Lumos Pharma (NASDAQ:LUMO)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024